Pazopanib activity confirmed in EWSR1-NFATC2 bone sarcoma

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.”